Bayer AG has had a fluctuating period in the market, with its stock showing significant highs and lows. Though its
profit forecast fell short of expectations and shares dropped due to a miss in the 2026 outlook, it demonstrated resilience in various instances. Bayer stock surged on various occasions, most notably after the US Supreme Court agreed to hear their
Roundup appeal, causing pre-market predictions to show a
10.32% rise as of March 17, 2026. However, gains were reversed following the decision to settle Roundup Litigation. Despite this, UBS saw potential opportunities for the German pharmaceutical giant, upgrading the stock to 'Buy.' It's also worthy to note an
88% surge in 2025 which may reflect a real turnaround following restructuring and litigation hopes. However, this positive momentum came in conjunction with
legal risks and losses that the company's CEO bought more shares in, indicating some level of confidence. Furthermore, the company has continuously made good strides in the area of
pharmaceuticals, specifically prostate cancer, and maintains a strong leadership in crop science. However, investor's concerns regarding inflated earnings, due to soccer transfers, led to a drop in shares.
BAYER Stocks News Analytics from Wed, 18 Jun 2025 07:00:00 GMT to Fri, 20 Mar 2026 05:35:28 GMT -
Rating 2
- Innovation -4
- Information 7
- Rumor -3
